177 related articles for article (PubMed ID: 31599393)
1. The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.
Aljohani AI; Toss MS; Kurozumi S; Joseph C; Aleskandarany MA; Miligy IM; Ansari RE; Mongan NP; Ellis IO; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jan; 179(1):79-90. PubMed ID: 31599393
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development.
Aljohani AI; Toss MS; Green AR; Rakha EA
Breast Cancer Res Treat; 2023 Apr; 198(3):423-435. PubMed ID: 36418517
[TBL] [Abstract][Full Text] [Related]
3. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Significance of Cyclin-Dependent Kinase 2 (CDK2) in Ductal Carcinoma In Situ and Early-Stage Invasive Breast Cancers.
Lashen A; Alqahtani S; Shoqafi A; Algethami M; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732271
[TBL] [Abstract][Full Text] [Related]
7. Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study.
Toss MS; Miligy IM; Gorringe KL; AlKawaz A; Mittal K; Aneja R; Ellis IO; Green AR; Roxanis I; Rakha EA
Mod Pathol; 2019 Oct; 32(10):1473-1485. PubMed ID: 31175326
[TBL] [Abstract][Full Text] [Related]
8. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers.
Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ
BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106
[TBL] [Abstract][Full Text] [Related]
9. Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer.
Aleskandarany MA; Sonbul S; Surridge R; Mukherjee A; Caldas C; Diez-Rodriguez M; Ashankyty I; Albrahim KI; Elmouna AM; Aneja R; Martin SG; Ellis IO; Green AR; Rakha EA
Br J Cancer; 2017 Oct; 117(8):1176-1184. PubMed ID: 28829761
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer.
Kariri YA; Alsaleem M; Joseph C; Alsaeed S; Aljohani A; Shiino S; Mohammed OJ; Toss MS; Green AR; Rakha EA
Breast Cancer Res Treat; 2021 Jan; 185(2):293-305. PubMed ID: 33073304
[TBL] [Abstract][Full Text] [Related]
11. Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Gorringe KL; McCaffrey L; AlKawaz A; Abidi A; Ellis IO; Green AR; Rakha EA
Mod Pathol; 2019 May; 32(5):639-649. PubMed ID: 30429518
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
13. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
Minemura H; Takagi K; Sato A; Yamaguchi M; Hayashi C; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
Breast Cancer; 2021 Jul; 28(4):915-926. PubMed ID: 33713004
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of Flap Endonuclease 1 (FEN1) in breast ductal carcinoma in situ.
Al-Kawaz A; Miligy IM; Toss MS; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
Breast Cancer Res Treat; 2021 Jul; 188(1):53-63. PubMed ID: 34117958
[TBL] [Abstract][Full Text] [Related]
15. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
16. The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).
Al-Kawaz A; Ali R; Toss MS; Miligy IM; Mohammed OJ; Green AR; Madhusudan S; Rakha EA
Breast Cancer Res Treat; 2021 Nov; 190(1):39-51. PubMed ID: 34406589
[TBL] [Abstract][Full Text] [Related]
17. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.
Boland GP; Butt IS; Prasad R; Knox WF; Bundred NJ
Br J Cancer; 2004 Jan; 90(2):423-9. PubMed ID: 14735188
[TBL] [Abstract][Full Text] [Related]
18. TBX3 promotes progression of pre-invasive breast cancer cells by inducing EMT and directly up-regulating SLUG.
Krstic M; Kolendowski B; Cecchini MJ; Postenka CO; Hassan HM; Andrews J; MacMillan CD; Williams KC; Leong HS; Brackstone M; Torchia J; Chambers AF; Tuck AB
J Pathol; 2019 Jun; 248(2):191-203. PubMed ID: 30697731
[TBL] [Abstract][Full Text] [Related]
19. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer.
Joseph C; Arshad M; Kurozomi S; Althobiti M; Miligy IM; Al-Izzi S; Toss MS; Goh FQ; Johnston SJ; Martin SG; Ellis IO; Mongan NP; Green AR; Rakha EA
Breast Cancer Res Treat; 2019 Apr; 174(2):387-399. PubMed ID: 30554343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
